National Cancer Institute, Research Contracts Branch, PSAS, 6120 Executive Blvd, EPS/Room 638, Bethesda, MD 20892-7227

B -- VITAMIN & MINERAL PILLS SOL NCI-RFQ00149-NR DUE 071700 POC Marsha Gorham, Purchasing Agent & Gail Zois, Contracting Officer The Division of Cancer Epidemiology and Genetics, National Cancer Institute plans to procure vitamin and mineral pills from Sino-American Shanghai Squibb Pharmaceuticals (SASS), Ltd., 6F Fu Xing Plaza, 109 Yan Dang Road, Shanghai, Peoples Republic of China 200020 on a sole source basis. Gastric cancer (GC) is one of the most common cancers in the world, including China. Available evidence suggests that a major subtype of GC represents the final stage of gastric mucosa over many years, and the process is heavily influenced by environmental factors. In 1995, investigators at the NCI and Beijing Institute for Cancer Research initiated a randomized multi-intervention trial among adults in Linqu County, Shandong Province, an area with one of the highest rates of stomach cancers in the world. Research using vitamin and mineral pills from this source has been continually conducted under these collaborative studies . Under a collaborative agreement between NCI and Sino-American Shanghai Squibb developed a special formula with the 250 mg vitamin C 100II alpha-tocopherol and 37.5 ug selenium and look -- like placebo according to the protocol of the shandong Intervention trial and made 5.91 million active vitamin/mineral pills and 5.91 placebos that have been used on the ongoing trial. In addition, quality control reports were provided and utilized within the study. The intervention trial has been extended until December 2001, and 2.26 million more active and 2.26 placebo capsules are required to continue this effort. through December 31, 2001. In order to ensure consistency of variables and data throughout the trial, it is essential that the same make of vitamin pill and placebo be used on the trial extension. Even slight changes in the formula and original source of the vitamins/minerals comprising the pills could be detrimental to the research. Since Sino-American Shanghai Squibb Pharmaceuticals (SASS), Ltd. developed this vitamin/mineral pill that has been solely utilized on the ongoing trials, it is the only source known to NCI that can meet the above supply requirements without affecting the study variables. If any interested party believes it can perform the above work and maintain the reliability of all data, it may submit a statement of capabilities. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform this requirement. Capability statements must be received in the contracting office by 3:00 p.m. EST, on July 17, 2000. If you have any questions, please contact Marsha Gorham, Purchasing Agent on (301) 402-4509. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. Please cite the solicitation number NCI-RFQ-00149-NR. Posted 06/28/00 (W-SN469522). (0180)

Loren Data Corp. http://www.ld.com (SYN# 0009 20000630\B-0001.SOL)